Wednesday, July 01, 2020 4:08:31 PM
1) CAFC agrees that weighing of SCs is wrong but "commercial success" and "unmet need" still cannot overcome obviousness (that's why we might need Kura)
2) CAFC agrees that weighing of SCs is wrong but it strike down commercial success (due to off-label contributions) as positive SC hence cannot overcome obviousness
Amarin needs to hammer home the reasons and scale of commercial success based on MARINE and ANCHOR. If it was only the TG>500 mg/dl population, Vascepa has served since 2012, it would be very small sales indeed. This fact underscores the long felt and hitherto unmet need for a TG lowering LDL and ApoB lowering drug, to decrease residual risk from remnant lipoproteins fulfilled by Amarin long before R-IT confirmd clinically how huge this benefit really is. This fact also underscores why off label prescription infringement (albeit not actively encouraged by generic company labeling)by writers of off label Gen Vascepa is a given..
HK
https://investorshub.advfn.com/uimage/uploads/2020/7/1/icuf[sales_vascepa_analysis.png
Recent AMRN News
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
